CC BY-NC-ND 4.0 · Endosc Int Open 2020; 08(05): E628-E635
DOI: 10.1055/a-1119-6509
Original article

High-quality colon cleansing and multiple neoplasia detection with 1L NER1006 versus mid-volume options: Post hoc analysis of phase 3 clinical trials

Michael S. Epstein
1   Investigative Clinical Research, Annapolis, Maryland, United States
,
Robert Benamouzig
2   Service de Gastroentérologie, Hôpital Avicenne, Bobigny, France
,
Juha Halonen
3   Medical Affairs, Norgine Ltd., Harefield, United Kingdom
,
Raf Bisschops
4   University Hospitals Leuven, Department of Gastroenterology and Hepatology, TARGID, KU Leuven, Belgium
› Author Affiliations

Abstract

Background and study aims Multiple neoplasia increase the risk of colorectal cancer. High-quality cleansing may improve adenoma detection. We assessed whether a new bowel preparation can improve colon cleansing and multiple lesion detection.

Patients and methods This post hoc analysis of two randomized clinical trials in Europe and the US assessed the per study and combined cleansing efficacy of overnight split dosing with (preparation + clear fluids) 1 + 1 L polyethylene glycol (PEG) NER1006 versus 2 + 1 L PEG + ascorbate (2LPEG) or 1 + 2 L oral sulfate solution (OSS) combined. Treatment-blinded central readers assessed cleansing quality using the Harefield Cleansing Scale (HCS). Patients with full segmental scoring were included. HCS segmental scores 0–4 (high-quality = HCS 3–4) were analyzed for NER1006 versus 2LPEG/OSS. Mean number of polyps or adenomas per patient (MPP/MAP) was calculated for treatments in patients with at least one polyp or adenoma.

Results In 1037 patients, NER1006 attained a greater rate of HCS 3 scores (29 % vs. 20 %; P < 0.001) and HCS 4 scores (20 % vs. 17 %; P = 0.007) versus 2LPEG/OSS. More polyps (678 versus 585) and adenomas (397 versus 331) were detected with NER1006 (N = 517) versus 2LPEG/OSS (N = 520). In all neoplasia-positive patients, with increasing minimal per-patient neoplasia multiplicity from 1 to 10, NER1006 numerically improved MPP (difference ± SE: 0.48 ± 0.24 to 3.89 ± 3.37) and MAP (0.47 ± 0.26 to 7.50 ± 9.00) versus 2LPEG/OSS.

Conclusions Low-volume NER1006 enhances high-quality cleansing versus medium-volume 2LPEG or OSS, individually and when combined. NER1006 may consequently facilitate the detection of multiple neoplasia in patients.

Supplementary material



Publication History

Received: 09 October 2019

Accepted: 08 January 2020

Article published online:
17 April 2020

© 2020. Owner and Copyright ©

© Georg Thieme Verlag KG
Stuttgart · New York

 
  • References

  • 1 Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014; 348: g2467
  • 2 Lin OS, Kozarek RA, Cha JM. Impact of sigmoidoscopy and colonoscopy on colorectal cancer incidence and mortality: an evidence-based review of published prospective and retrospective studies. Intest Res 2014; 12: 268-274
  • 3 Nishihara R, Wu K, Lochhead P. et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369: 1095-1105
  • 4 Corley DA, Jensen CD, Marks AR. et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014; 370: 1298-1306
  • 5 Kaminski MF, Wieszczy P, Rupinski M. et al. Increased rate of adenoma detection associates with reduced risk of colorectal cancer and death. Gastroenterology 2017; 153: 98-105
  • 6 Amano T, Nishida T, Shimakoshi H. et al. Number of polyps detected is a useful indicator of quality of clinical colonoscopy. Endosc Int Open 2018; 6: E878-E884
  • 7 Gessl I, Waldmann E, Penz D. et al. Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. Gastrointest Endosc 2019; 89: 496-502
  • 8 Oh CH, Lee CK, Kim J-W. et al. Suboptimal bowel preparation significantly impairs colonoscopic detection of non-polypoid colorectal neoplasms. Dig Dis Sci 2015; 60: 2294-2303
  • 9 Clark BT, Protiva P, Nagar A. et al. Quantification of adequate bowel preparation for screening or surveillance colonoscopy in men. Gastroenterology 2016; 150: 396-405; quiz e14-15
  • 10 Clark BT, Laine L. High-quality bowel preparation is required for detection of sessile serrated polyps. Clin Gastroenterol Hepatol 2016; 14: 1155-1162
  • 11 Pontone S, Hassan C, Maselli R. et al. Multiple zonal and multi-zone adenoma detection rates according to quality of cleansing during colonoscopy. United Eur Gastroenterol J 2016; 4: 778-783
  • 12 Hassan C, Bisschops R, Heimanson Z. et al. Tu1074 Impact of cleansing quality using the Harefield Cleansing Scale and polyp and adenoma detection rates: a post hoc analysis of three phase 3 randomized trials. Gastrointest Endosc 2018; 87: ab521-ab522
  • 13 Guo R, Wang Y-J, Liu M. et al. The effect of quality of segmental bowel preparation on adenoma detection rate. BMC Gastroenterol 2019; 19: 119
  • 14 Laish I, Sergeev I, Stein A. et al. Risk of metachronous advanced lesions after resection of diminutive and small non-advanced adenomas. Clin Res Hepatol Gastroenterol 2019; 43: 201-207
  • 15 Kim NH, Jung YS, Lee MY. et al. Risk of developing metachronous advanced colorectal neoplasia after polypectomy in patients with multiple diminutive or small adenomas. Am J Gastroenterol 2019; 114: 1657-1664
  • 16 Vleugels JLA, Hassan C, Senore C. et al. Diminutive polyps with advanced histologic features do not increase risk for metachronous advanced colon neoplasia. Gastroenterology 2019; 156: 623-634.e3
  • 17 Anderson JC, Rex DK, Robinson C. et al. Association of small versus diminutive adenomas and the risk for metachronous advanced adenomas: data from the New Hampshire Colonoscopy Registry. Gastrointest Endosc 2019; 90: 495-501
  • 18 Hartstein JD, Vemulapalli KC, Rex DK. The predictive value of small versus diminutive adenomas for subsequent advanced neoplasia. Gastrointest Endosc 2019; 91: 614-621
  • 19 Løberg M, Kalager M, Holme Ø. et al. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med 2014; 371: 799-807
  • 20 Bonnington SN, Sharp L, Rutter MD. Post-polypectomy surveillance in the English bowel cancer screening programme: results of first surveillance. Endoscopy 2019; 51: S116.OP335
  • 21 Bonnington SN, Sharp L, Rutter MD. Post-polypectomy surveillance in the English bowel cancer screening programme: multivariate logistic regression of factors influencing advanced adenoma detection at first surveillance. Endoscopy 2019; 51: S153.ePP79
  • 22 Lieberman D, Sullivan BA, Hauser ER. et al. Baseline colonoscopy findings associated with 10-year outcomes in a screening cohort undergoing colonoscopy surveillance. Gastroenterology 2020; 158: 862-874.e8
  • 23 Meester RG, Doubeni CA, Lansdorp-Vogelaar I. et al. Variation in adenoma detection rate and the lifetime benefits and cost of colorectal cancer screening: a microsimulation model. JAMA 2015; 313: 2349-2358
  • 24 Zimmermann-Fraedrich K, Sehner S, Rex DK. et al. Right-sided location not associated with missed colorectal adenomas in an individual-level reanalysis of tandem colonoscopy studies. Gastroenterology 2019; 157: 660-671
  • 25 Halphen M, Heresbach D, Gruss H-J. et al. Validation of the Harefield Cleansing Scale: a tool for the evaluation of bowel cleansing quality in both research and clinical practice. Gastrointest Endosc 2013; 78: 121-131
  • 26 IQVIA MIDAS World Review Pack 2019. Market: Worldwide market of bowel cleansing products only (excl. enemas). Data supplied by IQVIA and analysed by Norgine
  • 27 DeMicco MP, Clayton LB, Pilot J. et al. Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: a randomized controlled phase 3 trial versus trisulfate. Gastrointest Endosc 2018; 87: 677-687.e3
  • 28 Bisschops R, Manning J, Clayton LB. et al. Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L polyethylene glycol + ascorbate: a randomized phase 3 trial. Endoscopy 2019; 51: 60-72
  • 29 Schreiber S, Baumgart DC, Drenth JPH. et al. Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial. Endoscopy 2019; 51: 73-84
  • 30 Kane SV, Ananthakrishnan AN. Toward reducing bias in clinical trials: central readers for endoscopic endpoints. Gastrointest Endosc 2016; 83: 198-200
  • 31 Kim B, Lee SD, Han KS. et al. Comparative evaluation of the efficacy of polyethylene glycol with ascorbic acid and an oral sulfate solution in a split method for bowel preparation: a randomized multicenter phase III clinical trial. Dis Colon Rectum 2017; 60: 426-432
  • 32 Lee HH, Lim CH, Kim JS. et al. Comparison between an oral sulfate solution and a 2 l of polyethylene glycol+ascorbic acid as a split dose bowel preparation for colonoscopy. J Clin Gastroenterol 2019; 53: e431-e437
  • 33 Nunes G, Barata AT, Santos CA. et al. Nutritional deficiency during colonoscopy preparation: the forgotten iatrogeny. Rev Esp Enferm Dig 2018; 110: 285-291
  • 34 Gu P, Lew D, Oh SJ. et al. Comparing the real-world effectiveness of competing colonoscopy preparations: results of a prospective trial. Am J Gastroenterol 2019; 114: 305-314
  • 35 Maida M, Morreale G, Sinagra E. et al. Effectiveness and tolerability of very low-volume preparation for colonoscopy: a prospective multicenter observational study. Endoscopy 2019; 51: S70